LAWRENCE GARBO M.D. NPI 1740276484

NPI Details

Lawrence Garbo, M.D. is a hematology and oncology internal medicine in Albany, NY with 49 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Lawrence Garbo, M.D. NPI is 1740276484. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF VERMONT COLLEGE OF MEDICINE
Graduation Year:1977

The provider's business location address is:

400 PATROON CREEK BLVD
SUITE 1
ALBANY, NY
ZIP 12206-004
Phone: (518) 489-0044
Fax: (518) 489-3591

The NPI 1740276484 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, iron sucrose, 1 mg (HCPCS:J1756)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Measurement of substance using immunoassay technique (HCPCS:83520)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Microscopic examination for white blood cells with manual cell count (HCPCS:85007)
• Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Vitamin d-3 level (HCPCS:82306)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Ct scan of chest with contrast (HCPCS:71260)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Blood test, clotting time (HCPCS:85610)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Magnesium level (HCPCS:83735)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Unclassified drugs (HCPCS:J3490)
• Drawing of blood for a medical problem (HCPCS:99195)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Collection of blood sample from implanted device (HCPCS:36591)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Ct scan of chest without contrast (HCPCS:71250)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Folic acid level, serum (HCPCS:82746)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session (HCPCS:G6015)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Detection test by immunoassay technique for hepatitis b surface antigen (HCPCS:87340)
• Hepatitis b core antibody measurement (HCPCS:86704)

The enumeration date for this NPI number is 9/27/2005 and was last updated on 3/19/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: